Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- SSI Said Ex-Employee Manipulated Data of Anti-Obesity Drug Study
December 25, 2013
- Daiichi Sankyo Files Edoxaban for AF, VTE New Indications
December 25, 2013
- Kyowa Kirin, LEO Pharma Collaborate to Market Fixed-Dose Combination Topical Treatment for Psoriasis in Japan
December 24, 2013
- Shire Names NBI Operating Officer Sunohara as New Japan Head
December 20, 2013
- Bristol to Sell Global Diabetes Biz to AstraZeneca; Deal Covers SGLT-2 Asset Transfer
December 20, 2013
- Can Epadel Continue to Maintain Sales in the Face of Competition from Lotriga and Generics?
December 20, 2013
- UMN, API, Yakult Conclude Another Joint Biosimilar Business Agreement in Oncology Field
December 19, 2013
- Astellas, Nichi-Iko Conclude Definitive Agreement on Transfer of Fuji Plant
December 19, 2013
- ViiV Healthcare, Shionogi Seal Copromotion Deal for Anti-HIV Treatment Dolutegravir
December 18, 2013
- Hyperlipidemia Treatment PCSK9 Inhibitors May Be Launched in Japan in 2016
December 17, 2013
- Ono Forms Subsidiary in S. Korea, Sets Sights on Anticancer Drug Sales
December 17, 2013
- AstraZeneca Japan to Draw on Overseas Dapagliflozin Data to Trump SGLT-2 Rivals
December 16, 2013
- Pfizer Japan to Reorganize in January with Stand-Alone Vaccines Unit
December 16, 2013
- Medipal to Venture into Contract PMS Business, Making Medi-Skette Its Wholly Owned Subsidiary
December 16, 2013
- AstraZeneca Japan Sees Annual Growth of Around 8%, Eyes Addition of 160 Reps
December 13, 2013
- Kyowa Kirin, Hisamitsu Launch Cancer Pain Treatment Abstral Sublingual Tablets
December 13, 2013
- IPSN Proposes Life Sciences Business Platform in Tokyo to Be Included in Mr Abe’s Special Zones
December 12, 2013
- Mochida Buys Back 100,000 Shares
December 12, 2013
- New Osaka Logistics Center to Go Live in January: Taisho
December 12, 2013
- Otsuka, Lundbeck to Codevelop Vaccine for Alzheimer’s Disease
December 12, 2013
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…